Biotech Values

[bladerunner1717]

Dew,

If the problem with the IDIX's 184/320 combo turns out to be a problem with the PI (320) and the way that it interacts with other anti-viral agents, then how do we know for sure that this is not a class-wide effect and will not happen again with other powerful PI's when used in combo with other types of anti-viral agents?

What is wrong with a two-nuke/non-nuke combo or a two-nuke/NS5A inhibitor? Why do you think a PI has to be part of the combo?


Bladerunner